Apr 15, 2008, 2008 - Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) announced that preclinical data from a model of small cell lung cancer (SCLC) show that following treatment with chemotherapy, once-daily oral administration of IPI-926 leads to a statistically significant delay in tumor re-growth, compared to vehicle control (p=0.01). These results suggest that inhibiting the Hedgehog pathway with IPI-926, Infinity's novel, potent Hedgehog pathway antagonist following chemotherapy delays tumor recurrence in SCLC. These data were presented today during the Annual Meeting of the American Association of Cancer Research (AACR) in San Diego, California... Infinity Pharmaceuticals' Press Release -
Apr 25, 2008
Infinity Pharmaceuticals' Hedgehog Antagonist Delays Tumor Growth Following Chemotherapy in Preclinical Model of Small Cell Lung Cancer
Apr 15, 2008, 2008 - Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) announced that preclinical data from a model of small cell lung cancer (SCLC) show that following treatment with chemotherapy, once-daily oral administration of IPI-926 leads to a statistically significant delay in tumor re-growth, compared to vehicle control (p=0.01). These results suggest that inhibiting the Hedgehog pathway with IPI-926, Infinity's novel, potent Hedgehog pathway antagonist following chemotherapy delays tumor recurrence in SCLC. These data were presented today during the Annual Meeting of the American Association of Cancer Research (AACR) in San Diego, California... Infinity Pharmaceuticals' Press Release -
